SEC Company Response from Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282) (SYRE) — May 25, 2017
Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282)
Date: May 25, 2017 · CIK: 0001636282 · Accession: 0001193125-17-183250
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217573
Letter
AEGLEA BIOTHERAPEUTICS, INC.
901 S. MoPac Expressway
Barton Oaks Plaza One, Suite 250
Austin, TX 78746
May 25, 2017
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance
Re: Aeglea BioTherapeutics, Inc.
Registration Statement on Form S-3
Filed May 1, 2017
File No. 333-217573
Via EDGAR - Acceleration Request
Requested Date: May 30, 2017
Requested Time: 4:30 p.m. Eastern Time
Ladies and Gentlemen:
Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Effie Toshav, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
Sincerely,
AEGLEA BIOTHERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP AEGLEA BIOTHERAPEUTICS, INC. 901 S. MoPac Expressway Barton Oaks Plaza One, Suite 250 Austin, TX 78746 May 25, 2017 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Suzanne Hayes Assistant Director Office of Healthcare and Insurance Re: Aeglea BioTherapeutics, Inc. Registration Statement on Form S-3 Filed May 1, 2017 File No. 333-217573 Via EDGAR - Acceleration Request Requested Date: May 30, 2017 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Registrant hereby authorizes Robert A. Freedman or Effie Toshav, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. Sincerely, AEGLEA BIOTHERAPEUTICS, INC. By: /s/ Charles N. York II Charles N. York II Chief Financial Officer cc: David G. Lowe, Chief Executive Officer Aeglea BioTherapeutics, Inc. Robert A. Freedman, Esq. Effie Toshav, Esq. Fenwick & West LLP